New hope for patients who Can't tolerate harsh chemo
NCT ID NCT07333274
Summary
This study is for people with advanced head and neck cancer who cannot receive standard platinum-based chemotherapy. It compares standard radiation therapy alone to radiation combined with a targeted drug called nimotuzumab. The goal is to see if adding nimotuzumab helps control the cancer better and improves survival without the severe side effects of chemotherapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD & NECK CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shandong First Medical University Affiliated Cancer Hospital
RECRUITINGShandong, Province, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.